18 May 2022: The Federal Ministers give a final decision (positive with conditions) for this trial
Trial reference:
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene